

# Roman Hajek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/935824/publications.pdf>

Version: 2024-02-01

470  
papers

29,324  
citations

12330

69  
h-index

5988

160  
g-index

495  
all docs

495  
docs citations

495  
times ranked

18973  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. <i>New England Journal of Medicine</i> , 2008, 359, 906-917.	27.0	1,787
2	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	27.0	1,407
3	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766.	27.0	1,246
4	Sepsis and septic shock. <i>Lancet, The</i> , 2018, 392, 75-87.	13.7	1,205
5	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	27.0	1,144
6	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	27.0	861
7	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology, The</i> , 2016, 17, 27-38.	10.7	723
8	Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1759-1769.	27.0	692
9	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. <i>Leukemia</i> , 2009, 23, 215-224.	7.2	686
10	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. <i>Leukemia</i> , 2010, 24, 1121-1127.	7.2	677
11	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
12	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv52-iv61.	1.2	619
13	Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. <i>Journal of Clinical Oncology</i> , 2007, 25, 3892-3901.	1.6	607
14	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	1.4	586
15	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	13.7	517
16	IMWG consensus on risk stratification in multiple myeloma. <i>Leukemia</i> , 2014, 28, 269-277.	7.2	500
17	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.	13.7	435
18	International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. <i>Leukemia</i> , 2009, 23, 1545-1556.	7.2	428

#	ARTICLE	IF	CITATIONS
19	TGF- $\beta$ 2 "an excellent servant but a bad master. Journal of Translational Medicine, 2012, 10, 183.	4.4	390
20	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 587-600.	1.6	330
21	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1327-1337.	10.7	320
22	Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2021, 32, 309-322.	1.2	316
23	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood, 2011, 118, 4519-4529.	1.4	309
24	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia, 2013, 27, 780-791.	7.2	294
25	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica, 2015, 100, 1254-1266.	3.5	289
26	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 1617-1629.	10.7	289
27	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood, 2011, 117, 4696-4700.	1.4	285
28	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncology, The, 2014, 15, 333-342.	10.7	256
29	Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematology, the, 2020, 7, e456-e468.	4.6	244
30	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE) Tj ETQq0 0 0 r8BT /Overlock 10 Tf	10.7	219
31	Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood, 2009, 113, 3435-3442.	1.4	213
32	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia, 2009, 23, 1904-1912.	7.2	207
33	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 396, 1563-1573.	13.7	188
34	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	13.7	187
35	Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2012, 30, 2475-2482.	1.6	185
36	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99, 232-242.	3.5	185

#	ARTICLE	IF	CITATIONS
37	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet, The</i> , 2021, 397, 2361-2371.	13.7	177
38	Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. <i>Leukemia</i> , 2013, 27, 711-717.	7.2	174
39	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	6.2	170
40	International Myeloma Working Group recommendations for global myeloma care. <i>Leukemia</i> , 2014, 28, 981-992.	7.2	162
41	Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 947-961.	3.6	144
42	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3459-3466.	1.6	138
43	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. <i>Leukemia</i> , 2009, 23, 1716-1730.	7.2	136
44	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021, 22, e105-e118.	10.7	136
45	Light Chain-Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4635-4641.	1.6	133
46	Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. <i>Haematologica</i> , 2014, 99, 360-364.	3.5	133
47	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.	6.2	126
48	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> , 2014, 99, 984-996.	3.5	124
49	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 652-660.	2.8	115
50	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	1.4	110
51	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	3.5	110
52	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	7.2	109
53	Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. <i>Leukemia</i> , 2011, 25, 749-760.	7.2	108
54	<sc>PD</sc>-inhibitors in haematological malignancies: update 2017. <i>Immunology</i> , 2017, 152, 357-371.	4.4	108

#	ARTICLE	IF	CITATIONS
55	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2020, 38, 3252-3260.	1.6	102
56	Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma. <i>PLoS ONE</i> , 2012, 7, e47077.	2.5	101
57	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). <i>Leukemia</i> , 2017, 31, 107-114.	7.2	98
58	Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2014, 99, 511-518.	3.5	94
59	Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2019, 133, 1953-1963.	1.4	94
60	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	3.7	90
61	Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. <i>British Journal of Haematology</i> , 2010, 149, 334-351.	2.5	88
62	Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 2431.	4.8	85
63	Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma – an IMWG Research Project. <i>Blood Cancer Journal</i> , 2018, 8, 123.	6.2	81
64	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	7.2	81
65	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	7.2	79
66	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	1.4	78
67	Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. <i>Blood Cancer Journal</i> , 2021, 11, 24.	6.2	77
68	The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. <i>Leukemia</i> , 2010, 24, 1700-1712.	7.2	76
69	Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. <i>Haematologica</i> , 2010, 95, 1548-1554.	3.5	75
70	Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. <i>British Journal of Haematology</i> , 2013, 163, 551-564.	2.5	74
71	Venetoclax: A new wave in hematooncology. <i>Experimental Hematology</i> , 2018, 61, 10-25.	0.4	73
72	The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. <i>Haematologica</i> , 2017, 102, 1617-1625.	3.5	71

#	ARTICLE	IF	CITATIONS
73	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	1.6	70
74	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 247-255.	1.6	69
75	Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. <i>Cancer</i> , 2008, 112, 1529-1537.	4.1	68
76	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	7.2	68
77	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	7.1	67
78	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.5	67
79	Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. <i>Blood Advances</i> , 2018, 2, 1633-1644.	5.2	66
80	Extramedullary disease in multiple myeloma – controversies and future directions. <i>Blood Reviews</i> , 2019, 36, 32-39.	5.7	66
81	The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. <i>Leukemia</i> , 2008, 22, 1479-1484.	7.2	65
82	Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. <i>Thyroid</i> , 2010, 20, 1209-1214.	4.5	61
83	Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. <i>Leukemia</i> , 2017, 31, 115-122.	7.2	61
84	Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 548-554.	2.0	59
85	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.	2.5	58
86	Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. <i>Haematologica</i> , 2013, 98, 784-788.	3.5	57
87	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4030-4041.	1.6	56
88	Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 352-355.	1.4	54
89	Carfilzomib+lenalidomide+dexamethasone vs lenalidomide+dexamethasone in relapsed multiple myeloma by previous treatment. <i>Blood Cancer Journal</i> , 2017, 7, e554-e554.	6.2	54
90	Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. <i>Medical Oncology</i> , 2000, 17, 2-15.	2.5	53

#	ARTICLE	IF	CITATIONS
91	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. Journal of Clinical Oncology, 2016, 34, 8000-8000.	1.6	52
92	Carfilzomib+dexamethasone vs bortezomib+dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia, 2017, 31, 1368-1374.	7.2	50
93	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leukemia and Lymphoma, 2010, 51, 1424-1443.	1.3	49
94	Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica, 2012, 97, 784-791.	3.5	49
95	Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica, 2011, 96, 1728-1732.	3.5	48
96	Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leukemia Research, 2013, 37, 829-837.	0.8	48
97	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncology, The, 2021, 22, 142-154.	10.7	46
98	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 2021, 11, 40.	6.2	46
99	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematology,the, 2021, 8, e934-e946.	4.6	46
100	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. British Journal of Haematology, 2017, 178, 571-582.	2.5	45
101	IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	4.1	45
102	Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer Journal, 2017, 7, e617-e617.	6.2	45
103	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. HemaSphere, 2021, 5, e528.	2.7	45
104	Serum miR-29a as a marker of multiple myeloma. Leukemia and Lymphoma, 2013, 54, 189-191.	1.3	44
105	Time-Varying Effects of Prognostic Factors Associated With Disease-Free Survival in Breast Cancer. American Journal of Epidemiology, 2009, 169, 1463-1470.	3.4	43
106	Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R) Tj ETQq0 0 0 rgt /Overlock 10 Tf 5	1.5	43
107	Monoclonal antibodies â€” A new era in the treatment of multiple myeloma. Blood Reviews, 2016, 30, 101-110.	5.7	43
108	Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplantation, 2005, 35, 159-164.	2.4	41

#	ARTICLE	IF	CITATIONS
109	Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. <i>Leukemia</i> , 2017, 31, 1727-1734.	7.2	41
110	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	2.5	41
111	Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. <i>Lancet Haematology</i> , 2018, 5, e299-e309.	4.6	41
112	Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. <i>Leukemia</i> , 2020, 34, 589-603.	7.2	41
113	Varicella-Zoster Virus Prophylaxis with Low-Dose Acyclovir in Patients with Multiple Myeloma Treated with Bortezomib. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 151-153.	1.4	40
114	Functionally Suppressive CD8 T Regulatory Cells Are Increased in Patients with Multiple Myeloma: A Cause for Immune Impairment. <i>PLoS ONE</i> , 2012, 7, e49446.	2.5	40
115	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2016, 122, 2050-2056.	4.1	40
116	Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. <i>European Journal of Haematology</i> , 2017, 99, 223-233.	2.2	40
117	The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. <i>PLoS ONE</i> , 2018, 13, e0202045.	2.5	40
118	Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. <i>Hematological Oncology</i> , 2013, 31, 41-48.	1.7	39
119	Influence of barrier material and barrier shape on blast wave mitigation. <i>Construction and Building Materials</i> , 2016, 120, 54-64.	7.2	39
120	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 2139-2150.	1.8	39
121	Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 44-49.	0.4	38
122	Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. <i>Leukemia and Lymphoma</i> , 2014, 55, 1489-1497.	1.3	37
123	Plasma cell leukemia: from biology to treatment. <i>European Journal of Haematology</i> , 2015, 95, 16-26.	2.2	37
124	Cytogenetics in multiple myeloma patients progressing into extramedullary disease. <i>European Journal of Haematology</i> , 2016, 97, 93-100.	2.2	37
125	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 646-646.	1.4	37
126	Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 920-927.	1.3	36



#	ARTICLE	IF	CITATIONS
127	PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. <i>Oncolmmunology</i> , 2016, 5, e1254856.	4.6	35
128	Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). <i>American Journal of Hematology</i> , 2019, 94, E35-E37.	4.1	35
129	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020, 13, 421-433.	2.2	34
130	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	2.7	33
131	Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy. <i>PLoS ONE</i> , 2015, 10, e0123866.	2.5	32
132	Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 23.	6.2	32
133	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. <i>ESMO Open</i> , 2022, 7, 100403.	4.5	32
134	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , 2022, 9, e98-e110.	4.6	32
135	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1049-1061.	1.8	31
136	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. <i>Blood Cancer Journal</i> , 2021, 11, 106.	6.2	31
137	Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1406-1408.	1.3	30
138	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens. <i>Blood</i> , 2010, 116, 622-622.	1.4	30
139	Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. <i>Annals of Hematology</i> , 2010, 89, 385-389.	1.8	29
140	Long Non-Coding RNAs in Multiple Myeloma. <i>Non-coding RNA</i> , 2019, 5, 13.	2.6	29
141	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020, 105, 193-200.	3.5	29
142	Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. <i>Haematologica</i> , 2020, 105, 1937-1947.	3.5	29
143	Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial). <i>Blood</i> , 2016, 128, 673-673.	1.4	29
144	Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. <i>Neoplasma</i> , 2010, 57, 29-34.	1.6	28

#	ARTICLE	IF	CITATIONS
145	Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e26-e27.	0.4	27
146	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). <i>Blood</i> , 2015, 126, 4250-4250.	1.4	27
147	Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting. <i>International Journal of Hematology</i> , 2010, 92, 314-319.	1.6	26
148	Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma – Phase II study results. <i>Neoplasma</i> , 2012, 59, 440-449.	1.6	26
149	Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. <i>British Journal of Haematology</i> , 2015, 171, 344-354.	2.5	26
150	Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial). <i>Blood</i> , 2016, 128, 242-242.	1.4	26
151	Intercellular Mitochondrial Transfer in the Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 1787.	3.7	25
152	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	1.6	25
153	Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. <i>Journal of Clinical Oncology</i> , 2019, 37, 8000-8000.	1.6	25
154	Genomewide profiling of copy number alteration in monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2016, 97, 568-575.	2.2	24
155	Immunomodulatory drugs in AL amyloidosis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 249-260.	4.4	24
156	Mechanism of immunomodulatory drugs in multiple myeloma. <i>Leukemia Research</i> , 2012, 36, 1218-1224.	0.8	23
157	Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma. <i>Journal of Translational Medicine</i> , 2013, 11, 77.	4.4	23
158	Genome-Wide Screening of Cytogenetic Abnormalities in Multiple Myeloma Patients Using Array-CGH Technique: A Czech Multicenter Experience. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	23
159	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	1.3	23
160	Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. <i>European Journal of Haematology</i> , 2020, 104, 190-197.	2.2	23
161	Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. <i>Leukemia</i> , 2022, 36, 288-291.	7.2	23
162	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. <i>Leukemia and Lymphoma</i> , 2017, 58, 2501-2504.	1.3	22

#	ARTICLE	IF	CITATIONS
163	Long Non-Coding RNAs in Multiple Myeloma. <i>Genes</i> , 2018, 9, 69.	2.4	22
164	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	3.5	22
165	Shared structural features of the 9aaTAD family in complex with CBP. <i>Molecular BioSystems</i> , 2015, 11, 844-851.	2.9	21
166	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. <i>Annals of Hematology</i> , 2021, 100, 2325-2337.	1.8	21
167	Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8501-8501.	1.6	21
168	Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres. <i>British Journal of Haematology</i> , 2022, 197, 302-305.	2.5	21
169	Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- driven nonapeptides or myeloma cell apoptotic bodies. <i>Neoplasma</i> , 2010, 57, 455-464.	1.6	20
170	Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 123-130.	0.4	20
171	Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. <i>BMC Cancer</i> , 2021, 21, 73.	2.6	20
172	A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2013, 122, 763-763.	1.4	20
173	The miR-29 family in hematological malignancies. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2015, 159, 184-191.	0.6	20
174	Nuclear organization of PML bodies in leukaemic and multiple myeloma cells. <i>Leukemia Research</i> , 2008, 32, 1866-1877.	0.8	19
175	High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. <i>Bone Marrow Transplantation</i> , 2008, 41, 51-54.	2.4	19
176	Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment. <i>Leukemia and Lymphoma</i> , 2013, 54, 1324-1326.	1.3	19
177	New Approaches to Management of Multiple Myeloma. <i>Current Treatment Options in Oncology</i> , 2014, 15, 157-170.	3.0	19
178	Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. <i>Leukemia</i> , 2017, 31, 2630-2641.	7.2	19
179	Monoclonal antibodies in the treatment of AL amyloidosis: co&#x00E9;targetting the plasma cell clone and amyloid deposits. <i>British Journal of Haematology</i> , 2020, 189, 228-238.	2.5	19
180	Successful early use of anti&#x00E9;SARS&#x00E9;CoV&#x00E9;2 monoclonal neutralizing antibodies in SARS&#x00E9;CoV&#x00E9;2 infected hematological patients &#x00E0; A Czech multicenter experience. <i>Hematological Oncology</i> , 2022, 40, 280-286.	1.7	19

#	ARTICLE	IF	CITATIONS
181	Dendritic Cell-based Immunotherapy for the Treatment of Hematological Malignancies. <i>Hematology</i> , 2003, 8, 97-104.	1.5	18
182	Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. <i>Journal of Translational Medicine</i> , 2016, 14, 150.	4.4	18
183	A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. <i>Haematologica</i> , 2018, 103, 1518-1526.	3.5	18
184	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. <i>Haematologica</i> , 2019, 104, 2358-2360.	3.5	18
185	Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. <i>British Journal of Haematology</i> , 2021, 193, 705-722.	2.5	18
186	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. <i>Blood</i> , 2019, 134, 693-693.	1.4	18
187	Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8006-8006.	1.6	18
188	Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation. <i>Neoplasma</i> , 2010, 57, 111-117.	1.6	17
189	Ixazomib+Thalidomide+Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. <i>British Journal of Cancer</i> , 2019, 121, 751-757.	6.4	17
190	Melflufen for relapsed and refractory multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1069-1078.	4.1	17
191	Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.. <i>Blood</i> , 2007, 110, 529-529.	1.4	17
192	Epigenetics of multiple myeloma after treatment with cytostatics and gamma radiation. <i>Leukemia Research</i> , 2009, 33, 1490-1498.	0.8	16
193	Multiple Myeloma Associated IgA Pemphigus: Treatment With Bortezomib- and Lenalidomide-Based Regimen. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 517-520.	0.4	16
194	Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: A single-center study of seven cases. <i>Acta Oncologica</i> , 2013, 52, 994-1001.	1.8	16
195	Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. <i>PLoS ONE</i> , 2015, 10, e0137294.	2.5	16
196	Genomewide association study on monoclonal gammopathy of unknown significance (MGUS). <i>European Journal of Haematology</i> , 2017, 99, 70-79.	2.2	16
197	Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e219-e240.	0.4	16
198	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020, 105, 1074-1080.	3.5	16

#	ARTICLE	IF	CITATIONS
199	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. <i>Blood Cancer Journal</i> , 2020, 10, 35.	6.2	16
200	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	4.1	16
201	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. <i>Blood</i> , 2020, 136, 37-38.	1.4	16
202	Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. <i>Blood</i> , 2011, 118, 811-811.	1.4	16
203	Expression of RAN, ZHX-2, and CHC1L genes in multiple myeloma patients and in myeloma cell lines treated with HDAC and Dnmts inhibitors. <i>Neoplasma</i> , 2010, 57, 482-487.	1.6	15
204	Proteomic Analysis in Multiple Myeloma Research. <i>Molecular Biotechnology</i> , 2011, 47, 83-93.	2.4	15
205	Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. <i>Acta Oncologica</i> , 2012, 51, 412-415.	1.8	15
206	Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia. <i>Genomics</i> , 2013, 102, 243-249.	2.9	15
207	Nestin expression throughout multistep pathogenesis of multiple myeloma. <i>British Journal of Haematology</i> , 2014, 164, 701-709.	2.5	15
208	Korean medicine clinical practice guideline for lumbar herniated intervertebral disc in adults: An evidence based approach. <i>European Journal of Integrative Medicine</i> , 2017, 9, 18-26.	1.7	15
209	The start of a new wave: Developments in proteasome inhibition in multiple myeloma. <i>European Journal of Haematology</i> , 2018, 101, 220-236.	2.2	15
210	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021, 96, 1120-1130.	4.1	15
211	ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety. <i>Blood</i> , 2020, 136, 9-10.	1.4	15
212	Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. <i>Blood</i> , 2020, 136, 7-8.	1.4	15
213	Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. <i>Blood</i> , 2014, 124, 79-79.	1.4	15
214	Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 8011-8011.	1.6	15
215	Epidemiology of Multiple Myeloma in the Czech Republic. <i>Klinicka Onkologie</i> , 2017, 30, 2S35-2S42.	0.3	15
216	Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 56243-56254.	1.8	15

#	ARTICLE	IF	CITATIONS
217	Second Autologous Transplantation for Multiple Myeloma Patients Relapsing after the First Autograft – a Pilot Study for the Evaluation of Experimental Maintenance Therapies. Report of the Prospective Non-Randomized Pilot Study of the Czech Myeloma Group. <i>Oncology Research and Treatment</i> , 2004, 27, 275-279.	1.2	14
218	Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Neoplasma</i> , 2009, 56, 526-532.	1.6	14
219	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2006-2011.	1.3	14
220	Lenalidomide: a new treatment option for Castleman disease. <i>Leukemia and Lymphoma</i> , 2012, 53, 2089-2091.	1.3	14
221	Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients. <i>Onc Immunology</i> , 2013, 2, e25619.	4.6	14
222	Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma. <i>Leukemia</i> , 2019, 33, 1817-1821.	7.2	14
223	Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. <i>Leukemia and Lymphoma</i> , 2020, 61, 377-386.	1.3	14
224	Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8509-8509.	1.6	14
225	Natural Killer Cells in the Malignant Niche of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 816499.	4.8	14
226	Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma. <i>Leukemia Research</i> , 2010, 34, 1007-1011.	0.8	13
227	Stem cell marker nestin is expressed in plasma cells of multiple myeloma patients. <i>Leukemia Research</i> , 2011, 35, 1008-1013.	0.8	13
228	Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma. <i>Nuclear Medicine and Biology</i> , 2012, 39, 429-436.	0.6	13
229	Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. <i>Leukemia and Lymphoma</i> , 2019, 60, 471-476.	1.3	13
230	Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. <i>Leukemia</i> , 2020, 34, 1187-1191.	7.2	13
231	Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. <i>British Journal of Haematology</i> , 2020, 190, 189-197.	2.5	13
232	DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 53-54.	1.4	13
233	Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial. <i>Blood</i> , 2020, 136, 26-26.	1.4	13
234	A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 536-536.	1.4	13

#	ARTICLE	IF	CITATIONS
235	Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine combinations. <i>Vaccine</i> , 2003, 21, 877-882.	3.8	12
236	Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. <i>Leukemia and Lymphoma</i> , 2017, 58, 2089-2100.	1.3	12
237	Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase III study. <i>British Journal of Haematology</i> , 2017, 178, 61-71.	2.5	12
238	A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. <i>European Journal of Haematology</i> , 2020, 104, 435-442.	2.2	12
239	Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product. <i>Targeted Oncology</i> , 2020, 15, 599-611.	3.6	12
240	ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI). <i>Blood</i> , 2019, 134, 3124-3124.	1.4	12
241	Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study. <i>Blood</i> , 2019, 134, 1887-1887.	1.4	12
242	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. <i>Blood</i> , 2020, 136, 50-51.	1.4	12
243	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015. <i>Blood</i> , 2011, 118, 475-475.	1.4	12
244	Nuclear topography of the 1q21 genomic region and Mcl-1 protein levels associated with pathophysiology of multiple myeloma. <i>Neoplasma</i> , 2009, 56, 404-413.	1.6	11
245	Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Significant Survival Benefit of Novel Drugs in Post-Transplantation Relapse. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 436-442.	1.4	11
246	IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 311-314.	1.9	11
247	Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing. <i>Journal of Clinical Pathology</i> , 2018, 71, 687-694.	2.0	11
248	Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. <i>Current Medical Research and Opinion</i> , 2018, 34, 775-783.	1.9	11
249	Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort. <i>Hematological Oncology</i> , 2020, 38, 412-414.	1.7	11
250	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	17.0	11
251	Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. <i>Future Oncology</i> , 2021, 17, 2499-2512.	2.4	11
252	LYMRIT 37-01: A Phase I/II Study of 177Lu-Lilotomab Satetraxetan (Betalutin®) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) – Analysis with 6-Month Follow-up. <i>Blood</i> , 2018, 132, 2879-2879.	1.4	11

#	ARTICLE	IF	CITATIONS
253	Registry of Monoclonal Gammopathies (RMG) in the Czech Republic. <i>Blood</i> , 2015, 126, 4514-4514.	1.4	11
254	Dendritic Cell Vaccines in the Treatment of Multiple Myeloma : Advances and Limitations. <i>Medical Oncology</i> , 2002, 19, 213-218.	2.5	10
255	Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy. <i>The Hematology Journal</i> , 2005, 5, 559-564.	1.4	10
256	Individual myeloma-specific T cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2010, 148, 859-867.	2.5	10
257	Association Study of Selected Genetic Polymorphisms and Occurrence of Venous Thromboembolism in Patients With Multiple Myeloma Who Were Treated With Thalidomide. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 414-420.	0.4	10
258	1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. <i>Leukemia and Lymphoma</i> , 2012, 53, 2500-2503.	1.3	10
259	Flow cytometry-based enumeration and functional characterization of cd8 t regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. , 2014, 86, 220-228.		10
260	Flow cytometry in immunoglobulin light chain amyloidosis: Short review. <i>Leukemia Research</i> , 2015, 39, 1131-1136.	0.8	10
261	Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. <i>Hematological Oncology</i> , 2017, 35, 408-419.	1.7	10
262	High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. <i>PLoS ONE</i> , 2017, 12, e0181487.	2.5	10
263	Cytarabine+G-CSF is more effective than cyclophosphamide+G-CSF as a stem cell mobilization regimen in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1107-1114.	2.4	10
264	Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study.. <i>Blood</i> , 2007, 110, 3603-3603.	1.4	10
265	Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2015, 159, 288-293.	0.6	10
266	Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2019, 163, 279-283.	0.6	10
267	CD38 targeted treatment for multiple myeloma. <i>Vnitřní Lekarství</i> , 2018, 64, 939-948.	0.2	10
268	Sepsis and septic shock. <i>Supportive Care in Cancer</i> , 1995, 3, 106-110.	2.2	9
269	Detection and Long-Term In Vivo Monitoring of Individual Tumor-Specific T Cell Clones in Patients with Metastatic Melanoma. <i>Journal of Immunology</i> , 2007, 178, 6789-6795.	0.8	9
270	Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. <i>European Journal of Haematology</i> , 2007, 79, 305-309.	2.2	9



#	ARTICLE	IF	CITATIONS
271	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 533-540.	0.4	9
272	Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia. <i>Journal of Cancer</i> , 2019, 10, 5041-5048.	2.5	9
273	A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. <i>Cancers</i> , 2020, 12, 1333.	3.7	9
274	Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. <i>Cells</i> , 2021, 10, 967.	4.1	9
275	Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies. <i>Frontiers in Pharmacology</i> , 2021, 12, 733890.	3.5	9
276	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. <i>Blood</i> , 2018, 132, 301-301.	1.4	9
277	Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients]. <i>Blood</i> , 2014, 124, 2071-2071.	1.4	9
278	Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network. <i>Haematologica</i> , 2021, 106, 1496-1499.	3.5	9
279	Centrosomal Disruption As Early Event in Myeloma Development. <i>Blood</i> , 2011, 118, 1806-1806.	1.4	9
280	Interdigitating Dendritic Cell Sarcoma of the Leg. <i>Onkologie</i> , 2009, 32, 364-365.	0.8	8
281	Flow cytometry based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. , 2013, , n/a-n/a.		8
282	High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 24-30.	0.4	8
283	Immunoparesis in MGUS – Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories. <i>Neoplasma</i> , 2015, 62, 827-832.	1.6	8
284	Combination of serum microRNA-20a and microRNA-20b as a marker for Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2015, 90, E51-2.	4.1	8
285	Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. <i>European Journal of Haematology</i> , 2016, 96, 119-127.	2.2	8
286	Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making. <i>MDM Policy and Practice</i> , 2019, 4, 238146831881425.	0.9	8
287	Randomized, placebo-controlled, phase 3 study of perfosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. <i>EJHaem</i> , 2020, 1, 94-102.	1.0	8
288	Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. <i>Blood Reviews</i> , 2021, 46, 100758.	5.7	8

#	ARTICLE	IF	CITATIONS
289	Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 3065-3065.	1.4	8
290	Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). <i>Blood</i> , 2015, 126, 30-30.	1.4	8
291	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). <i>Blood</i> , 2015, 126, 731-731.	1.4	8
292	Flow Cytometric Phenotyping and Analysis of T Regulatory Cells in Monoclonal Gammopathy Patients.. <i>Blood</i> , 2009, 114, 2819-2819.	1.4	8
293	Identification of patients at high risk of secondary extramedullary multiple myeloma development. <i>British Journal of Haematology</i> , 2021, , .	2.5	8
294	Interlaboratory study of free monoclonal immunoglobulin light chain quantification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 89-92.	2.3	7
295	Successful Anakinra Therapy in 2 Patients with Schnitzler Syndrome. <i>Onkologie</i> , 2011, 34, 265-268.	0.8	7
296	Bone marrow plasma cell separation “ validation of separation algorithm. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1139-40.	2.3	7
297	Myeloma Genetics International Consortium. <i>Leukemia and Lymphoma</i> , 2012, 53, 796-800.	1.3	7
298	A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2017, 99, 80-90.	2.2	7
299	Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2019, 187, 447-458.	2.5	7
300	Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. <i>Cancers</i> , 2019, 11, 1735.	3.7	7
301	Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. <i>European Journal of Health Economics</i> , 2020, 21, 219-233.	2.8	7
302	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	6.2	7
303	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. <i>Clinical Cancer Research</i> , 2021, 27, 3695-3703.	7.0	7
304	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. <i>American Journal of Hematology</i> , 2021, 96, E383-E386.	4.1	7
305	Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 45-46.	1.4	7
306	Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study. <i>Blood</i> , 2017, 130, 901-901.	1.4	7

#	ARTICLE	IF	CITATIONS
307	Efficacy and tolerability of <sc>onceâ€week</sc> selinexor, bortezomib, and dexamethasone in comparison with standard <sc>twiceâ€week</sc> bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the <sc>BOSTON</sc> study. American Journal of Hematology, 2022, 97, .	4.1	7
308	Salvage treatment with upfront melphalan 100Âmg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma. Annals of Hematology, 2010, 89, 483-487.	1.8	6
309	Prognostic significance of morphological assessment of plasma cells in multiple myeloma. Neoplasma, 2011, 58, 554-560.	1.6	6
310	The problems of proteinuria measurement in urine with presence of Bence Jones protein. Clinical Biochemistry, 2011, 44, 403-405.	1.9	6
311	Molecular heterogeneity and centrosome-associated genes in multiple myeloma. Leukemia and Lymphoma, 2013, 54, 1982-1988.	1.3	6
312	Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. Gene, 2016, 591, 490-498.	2.2	6
313	WaldenstrÃ¶mâ€™s macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection. European Journal of Haematology, 2017, 99, 469-478.	2.2	6
314	The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma. Anticancer Research, 2018, 38, 5087-5092.	1.1	6
315	Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Cancer Medicine, 2018, 7, 4132-4145.	2.8	6
316	Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia. British Journal of Haematology, 2021, 195, 95-107.	2.5	6
317	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. Journal of Clinical Oncology, 2013, 31, 8517-8517.	1.6	6
318	CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. Oncotarget, 2016, 7, 78605-78618.	1.8	6
319	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. International Journal of Molecular Sciences, 2021, 22, 11470.	4.1	6
320	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. Blood, 2021, 138, 153-153.	1.4	6
321	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. Blood, 2021, 138, 3793-3793.	1.4	6
322	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: <sc>IKEMA</sc> subgroup analysis. American Journal of Hematology, 2023, 98, .	4.1	6
323	Sepsis and septic shock. Supportive Care in Cancer, 1995, 3, 111-119.	2.2	5
324	Isolation and Expansion of Allogeneic Myeloma-Specific Interferon-Gamma Producing T Cells for Adoptive Immunotherapy. Medical Oncology, 2006, 23, 377-384.	2.5	5

#	ARTICLE	IF	CITATIONS
325	<i>In vitro</i> activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. <i>Journal of Immunotoxicology</i> , 2009, 6, 243-248.	1.7	5
326	Cytokine analysis in a patient with relapsing Kikuchi-Fujimoto disease. <i>Leukemia and Lymphoma</i> , 2012, 53, 743-745.	1.3	5
327	Analysis of B-Cell Subpopulations in Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e61-e71.	0.4	5
328	Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 375-392.	2.2	5
329	Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 3717.	2.4	5
330	Transcriptomic Profiling of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): A New Model to Understand Disease Dissemination. <i>Blood</i> , 2018, 132, 245-245.	1.4	5
331	Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2018, 132, 1971-1971.	1.4	5
332	Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 3423-3423.	1.4	5
333	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. <i>Blood</i> , 2015, 126, 1844-1844.	1.4	5
334	Predictors of Overall Survival (OS) in Patients with Multiple Myeloma (MM) Initiating First- and Second-Line Treatment in the Czech Republic. <i>Blood</i> , 2016, 128, 3607-3607.	1.4	5
335	Czech Registry of Monoclonal Gammopathies – Technical Solution, Data Collection and Visualisation. <i>Klinicka Onkologie</i> , 2017, 30, 2S43-2S50.	0.3	5
336	Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers?. <i>Clinical Hematology International</i> , 2020, 2, 133.	1.7	5
337	Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. <i>British Journal of Haematology</i> , 2022, 198, 988-993.	2.5	5
338	Capillary immunotyping electrophoresis and high resolution two-dimensional electrophoresis for the detection of $\kappa$ 4-heavy chain disease. <i>Clinica Chimica Acta</i> , 2008, 389, 171-173.	1.1	4
339	Chromatin Structure and Epigenetics of Tumour Cells: A Review. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2009, 9, 51-61.	0.7	4
340	Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma. <i>Annals of Hematology</i> , 2011, 90, 1441-1447.	1.8	4
341	Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies. , 0, , .		4
342	The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2014, 55, 11-18.	1.3	4

#	ARTICLE	IF	CITATIONS
343	MicroRNAs in urine are not biomarkers of multiple myeloma. <i>Journal of Negative Results in BioMedicine</i> , 2015, 14, 16.	1.4	4
344	Centrosome amplification and clonal evolution in multiple myeloma: Short review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 116-121.	4.4	4
345	Activity of aldehyde dehydrogenase in B-cell and plasma cell subsets of monoclonal gammopathy patients and healthy donors. <i>European Journal of Haematology</i> , 2017, 98, 19-25.	2.2	4
346	Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies. <i>Journal of Clinical Pathology</i> , 2017, 70, 847-853.	2.0	4
347	Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?. <i>Disease Markers</i> , 2019, 2019, 1-6.	1.3	4
348	Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma – analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. <i>Neoplasma</i> , 2019, 66, 499-505.	1.6	4
349	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1793-1804.	1.8	4
350	ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM) – Optimal dose, updated efficacy and safety results.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8037-8037.	1.6	4
351	Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib,) Tj ETQq1 1 0.784314 rgBT /Overlock 1017 1959-1959.	1.4	4
352	OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2019, 134, 3163-3163.	1.4	4
353	Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study. <i>Blood</i> , 2020, 136, 42-44.	1.4	4
354	Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95). <i>Blood</i> , 2020, 136, 46-48.	1.4	4
355	Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry. <i>Klinicka Onkologie</i> , 2017, 30, 2S21-2S28.	0.3	4
356	Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. <i>Blood Advances</i> , 2022, 6, 4506-4515.	5.2	4
357	Treatment of Chronic Myeloid Leukemia with Autologous. <i>Medical Oncology</i> , 2003, 20, 69-76.	2.5	3
358	Association of aneuploidy category with centrosome amplification in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2011, 52, 2020-2022.	1.3	3
359	10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group. <i>Leukemia Research</i> , 2013, 37, 1063-1069.	0.8	3
360	Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting. <i>Oncology and Therapy</i> , 2019, 7, 141-157.	2.6	3

#	ARTICLE	IF	CITATIONS
361	Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review. <i>BMJ Open</i> , 2020, 10, e034209.	1.9	3
362	Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1.) <i>Tj ETQq0100 rgBT /Overlock 1</i>		
363	Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine. <i>Blood Advances</i> , 2021, , .	5.2	3
364	Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial. <i>Blood</i> , 2018, 132, 3186-3186.	1.4	3
365	Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study. <i>Blood</i> , 2020, 136, 35-36.	1.4	3
366	Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study. <i>Blood</i> , 2020, 136, 17-18.	1.4	3
367	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. <i>Blood</i> , 2020, 136, 4-6.	1.4	3
368	Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study. <i>Blood</i> , 2020, 136, 32-34.	1.4	3
369	Regulatory T Cells Predicts Progression in Previously Untreated Myeloma Patients and Treatment by Cyclophosphamide, Thalidomide Plus Dexamethasone Reduces Regulatory T Cells. <i>Blood</i> , 2011, 118, 2870-2870.	1.4	3
370	Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials. <i>Blood</i> , 2014, 124, 198-198.	1.4	3
371	Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients. <i>Blood</i> , 2014, 124, 2043-2043.	1.4	3
372	Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2015, 126, 2096-2096.	1.4	3
373	Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). <i>Blood</i> , 2015, 126, 729-729.	1.4	3
374	Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population. <i>Blood</i> , 2016, 128, 3333-3333.	1.4	3
375	Identification of Phenotype Profile Related to the Extramedullary Involvement in Multiple Myeloma Relapse. <i>Blood</i> , 2016, 128, 5653-5653.	1.4	3
376	CD38-targeted treatment for multiple myeloma. <i>Vnitri Lekarstvi</i> , 2018, 64, 939-948.	0.2	3
377	Bone Mineral Density in Multiple Myeloma Patients after Intravenous Clodronate Therapy. <i>Vienna Clinical Weekly</i> , 2001, 28, 38-42.	0.9	2
378	Interleukin-2 Activation of Haematopoietic Stem Cells. <i>Vienna Clinical Weekly</i> , 2002, 29, 61-67.	0.9	2

#	ARTICLE	IF	CITATIONS
379	Long-Term Outcomes and Treatment Patterns in Patients with Symptomatic Multiple Myeloma in the Real-World Setting: A Retrospective Analysis of the Czech Rmg Registry. <i>Value in Health</i> , 2016, 19, A158.	0.3	2
380	MRS. , 2018, , .		2
381	Simplified novel prognostic score for real-life older adults with multiple myelomaâ€”registry-based analysis. <i>Annals of Hematology</i> , 2019, 98, 951-962.	1.8	2
382	Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. <i>Haematologica</i> , 2021, 106, 601-604.	3.5	2
383	Washing transplants with Sepax 2 reduces the incidence of side effects associated with autologous transplantation and increases patients' comfort. <i>Transfusion</i> , 2021, 61, 2430-2438.	1.6	2
384	The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data. <i>Blood</i> , 2018, 132, 1967-1967.	1.4	2
385	Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study. <i>Blood</i> , 2019, 134, 1845-1845.	1.4	2
386	Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2019, 134, 3139-3139.	1.4	2
387	Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients â‰¥ 65 Years,. <i>Blood</i> , 2011, 118, 3988-3988.	1.4	2
388	Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8525-8525.	1.6	2
389	Bortezomib retreatment is effective in relapsed multiple myeloma patients â€” real-life clinical practice data. <i>Neoplasma</i> , 2020, 67, 178-184.	1.6	2
390	Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 927-927.	1.4	2
391	Osteolytic bone lesions, hypercalcemia and paraprotein, but not a myeloma: case report and review of literature. <i>Vnitřní Lekarství</i> , 2020, 66, 316-321.	0.2	2
392	B Cell Transcriptional Coactivator <i>POU2AF1</i> (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication. <i>Blood</i> , 2021, 138, 2670-2670.	1.4	2
393	Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies. <i>American Journal of Hematology</i> , 2022, , .	4.1	2
394	Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. <i>Blood Cancer Journal</i> , 2022, 12, 60.	6.2	2
395	Regulatory Cells and Multiple Myeloma. , 2012, , .		1
396	A Global Treatment Standard in Multiple Myeloma (MM) Remains Elusive Despite Advances in Care over 15 years: First Results from INSIGHT MM, the Largest Global Prospective, Observational MM Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S247-S248.	0.4	1

#	ARTICLE	IF	CITATIONS
397	PS1419 COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US. HemaSphere, 2019, 3, 652-653.	2.7	1
398	Real-world comparison of ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e271-e272.	0.4	1
399	PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA. HemaSphere, 2019, 3, 616.	2.7	1
400	A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e629-e644.	0.4	1
401	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.. Journal of Clinical Oncology, 2021, 39, 8034-8034.	1.6	1
402	Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. European Journal of Haematology, 2021, 107, 466-474.	2.2	1
403	Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone. Blood, 2020, 136, 43-44.	1.4	1
404	Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study. Blood, 2020, 136, 1-2.	1.4	1
405	Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.. Blood, 2007, 110, 2735-2735.	1.4	1
406	Impact of 1q21 Amplification Alone and in Combination with Other Genetic Abnormalities on Outcome in Multiple Myeloma Patients Treated with Thalidomide-Based Regimens. Blood, 2011, 118, 2874-2874.	1.4	1
407	Cell Cycle Gene Sets Coordination In Multiple Myeloma and Plasma Cell Leukemia. Blood, 2013, 122, 1901-1901.	1.4	1
408	Somatic Mutation Spectrum in Monoclonal Gammopathy of Undetermined Significance Compared to Multiple Myeloma. Blood, 2014, 124, 3346-3346.	1.4	1
409	Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic. Blood, 2014, 124, 3376-3376.	1.4	1
410	Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG). Blood, 2014, 124, 5682-5682.	1.4	1
411	Comparative Effectiveness of Daratumumab Monotherapy Versus a Real-World Historical Control from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients. Blood, 2016, 128, 3332-3332.	1.4	1
412	Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).. Journal of Clinical Oncology, 2010, 28, 8133-8133.	1.6	1
413	Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients. Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia, 2015, 159, 554-561.	0.6	1
414	Flow Cytometric Phenotyping and Analysis of CD8 Regulatory and Suppressor Cells In Multiple Myeloma. Blood, 2010, 116, 2947-2947.	1.4	1



#	ARTICLE	IF	CITATIONS
415	Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood, 2014, 124, 3448-3448.	1.4	1
416	Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).. Journal of Clinical Oncology, 2016, 34, 8045-8045.	1.6	1
417	Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity. Blood, 2016, 128, 2072-2072.	1.4	1
418	Deregulated Expression of Long Non-Coding RNAs UCA1, NEAT1 and BDNF-As in Multiple Myeloma. Blood, 2016, 128, 2073-2073.	1.4	1
419	The Value of Risk Stratification Tools in Multiple Myeloma (MM) in the Real-World: Validation of the Revised- International Staging System (R-ISS) at Initiation of Treatment and Relevance of the ISS and the R-ISS for Risk Stratification in the Relapsed Setting Using Data from the Czech Registry of Monoclonal Gammopathies (RMG). Blood, 2016, 128, 2418-2418.	1.4	1
420	Gene Expression Profile of Circulating Myeloma Cells Reveals CD44 and CD97 (ADGRE5) Overexpression. Blood, 2016, 128, 5639-5639.	1.4	1
421	Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice. Blood, 2021, 138, 2716-2716.	1.4	1
422	Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2021, 138, 2764-2764.	1.4	1
423	Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone. Blood, 2020, 136, 39-41.	1.4	1
424	O58 Correlation between chromosomal aberrations and standard prognostic factors in patients with multiple myeloma undergoing autologous stem cell transplantation. Blood Reviews, 2007, 21, S85.	5.7	0
425	P141 Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?. Blood Reviews, 2007, 21, S131.	5.7	0
426	Strategies for the Treatment of Multiple Myeloma in 2013: Moving Toward the Cure. , 0, , .		0
427	Heterogeneity and Plasticity of Multiple Myeloma. , 2013, , .		0
428	Incidence of cytogenetic aberrations in two B-cell lineage subpopulations in multiple myeloma patients analyzed by combination of whole-genome profiling and FISH. Neoplasma, 2014, 61, 48-55.	1.6	0
429	Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e93.	0.4	0
430	Adjusted Comparison of Daratumumab Monotherapy Versus Real-World Historical Control Data From The Czech Republic in Heavily Pre-Treated and Highly Refractory Multiple Myeloma Patients. Value in Health, 2016, 19, A711.	0.3	0
431	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e9.	0.4	0
432	Addressing Unmet Medical Needs in Maintenance Treatment for Newly Diagnosed Multiple Myeloma (NDMM). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S248-S249.	0.4	0

#	ARTICLE	IF	CITATIONS
433	A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e4-e5.	0.4	0
434	HDAC8 Mediates Homologous Recombination and Cytoskeleton Integrity in Myeloma with Potential Impact on Cell Growth and Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e127-e128.	0.4	0
435	Predicting Treatment Response of Multiple Myeloma Patients Using Tumor Specific cell-free DNA. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e177-e178.	0.4	0
436	Urine immunofixation is not necessary for CR definition in myeloma patients with complete M protein molecule. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e180-e181.	0.4	0
437	Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e293.	0.4	0
438	Registry of Monoclonal Gammopathies (RMG) - the monitored real-world database of the Czech Myeloma Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e324-e325.	0.4	0
439	Angiotensin-I Converting Enzyme Inhibitors and the Survival of Patients with Multiple Myeloma Treated by Autologous Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 944-944.	1.4	0
440	Monitoring of Dendritic Cell Numbers in Patients during the Treatment of Multiple Myeloma.. <i>Blood</i> , 2005, 106, 5096-5096.	1.4	0
441	Identification and Expansion of Myeloma-Specific Cytotoxic T Cells In Vitro.. <i>Blood</i> , 2005, 106, 5138-5138.	1.4	0
442	Expression of MAGE-A1 and MAGE-A3 in Bone Marrow from Monoclonal Gammopathy to Myeloma Patients.. <i>Blood</i> , 2007, 110, 4752-4752.	1.4	0
443	Phenotypic Analysis of Plasma Cells in Monoclonal Gammopathy and Multiple Myeloma Subjects.. <i>Blood</i> , 2007, 110, 4755-4755.	1.4	0
444	Low Molecular Weight Heparin in Sufficient Dose of 70 IU/kg as an Effective and Safe Thromboprophylaxis in Patients with Newly Diagnosed Multiple Myeloma during Conventional VAD Induction Therapy.. <i>Blood</i> , 2007, 110, 2732-2732.	1.4	0
445	The effect of pegylated liposomal doxorubicin plus bortezomib in multiple myeloma patients with renal insufficiency. <i>Journal of Clinical Oncology</i> , 2008, 26, 8562-8562.	1.6	0
446	Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments In Patients with Relapsed or Refractory Multiple Myeloma: Evaluation of Peripheral Neuropathy In the First 1,011 Patients. <i>Blood</i> , 2010, 116, 1939-1939.	1.4	0
447	Association Study of Ploidy Category with Mitotic Disruption In Multiple Myeloma. <i>Blood</i> , 2010, 116, 2952-2952.	1.4	0
448	High-Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma Group. <i>Blood</i> , 2012, 120, 4528-4528.	1.4	0
449	Extramedullary Relapse of Multiple Myeloma - Plasma Cells Characteristics.. <i>Blood</i> , 2012, 120, 2935-2935.	1.4	0
450	Genome Wide Profiling Of Chromosomal Abnormalities In 37 Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS). <i>Blood</i> , 2013, 122, 1874-1874.	1.4	0

#	ARTICLE	IF	CITATIONS
451	The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. <i>Blood</i> , 2014, 124, 4740-4740.	1.4	0
452	Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group. <i>Blood</i> , 2014, 124, 2117-2117.	1.4	0
453	Does AL Amyloidosis Have Unique Gene Expression Profile? Meta-Analysis Results. <i>Blood</i> , 2014, 124, 5689-5689.	1.4	0
454	Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 1974-1974.	1.4	0
455	Copy Number Variants Modulation and Their Clinical Impact in Multiple Myeloma. <i>Blood</i> , 2015, 126, 5304-5304.	1.4	0
456	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. <i>Blood</i> , 2016, 128, 3276-3276.	1.4	0
457	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. <i>Blood</i> , 2016, 128, 995-995.	1.4	0
458	European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib. <i>Blood</i> , 2016, 128, 3331-3331.	1.4	0
459	Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2018, 36, e20049-e20049.	1.6	0
460	Treatment Outcomes of Real Life Elderly Multiple Myeloma Patients: A Analysis from Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2018, 132, 2019-2019.	1.4	0
461	Abstract CT080: Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104). , 2019, . .		0
462	The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone. <i>Blood</i> , 2019, 134, 5832-5832.	1.4	0
463	Efficacy and safety of ABP 798 compared with rituximab: Results from the comparative clinical study in patients with non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , 2020, 38, 8044-8044.	1.6	0
464	Altered Expression of Epigenetic Modifiers Identifies Novel Biomarkers and Therapeutic Targets in AL Amyloidosis. <i>Blood</i> , 2021, 138, 4719-4719.	1.4	0
465	Prognostic Value of PET/CT Performed Day +100 Post Autologous Stem Cell Transplantation in Multiple Myeloma: Real-World Single Center Experience. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
466	Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
467	Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study. <i>Blood</i> , 2020, 136, 48-50.	1.4	0
468	Exploring POU2AF1 (BOB-1) Dependency and Transcription Addiction in Multiple Myeloma. <i>Blood</i> , 2020, 136, 49-49.	1.4	0

#	ARTICLE	IF	CITATIONS
469	Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling. Blood, 2020, 136, 16-17.	1.4	0
470	Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients. Blood, 2020, 136, 40-42.	1.4	0